MAP Pharma (MAPP) Shares Halted; FDA Decision on Levadex Expected; Watch Nektar (NKTR), Allergan (AGN)
Tweet
Share
E-mail
Get Alerts MAPP Hot Sheet
Join SI Premium – FREE
Shares of MAP Pharma (Nasdaq: MAPP) were halted up nearly 7 percent as the FDA's PDUFA deadline is today, March 26th. The Administration's decision on the company's migraine treatment Levadex will likely be out after the market closes this afternoon.
Traders should also be watching shares of Allergan (NYSE: AGN) and Nektar Therapeutics (Nasdaq: NKTR). If approved, MAP would be selling Levadex with Allergan and pay royalties to Nektar.
Shares of Nektar are up 4 percent at last check while shares of Allergan are up about 1.2 percent.
Traders should also be watching shares of Allergan (NYSE: AGN) and Nektar Therapeutics (Nasdaq: NKTR). If approved, MAP would be selling Levadex with Allergan and pay royalties to Nektar.
Shares of Nektar are up 4 percent at last check while shares of Allergan are up about 1.2 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hunterbrook bullish on Modine Manufacturing (MOD)
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
